Industry News

Biotechnology Industry News

Leo Pharma is sticking to its…

August 17th, 2026|FierceBiotech|

Leo Pharma is sticking to its mission of strengthening its pipeline in 2026, penning a $435 million deal for a rare skin disease drug from Tanabe Pharma that's awaiting an approval decision by the FDA.

Antibody platform business OmniAb…

August 17th, 2026|FierceBiotech|

Antibody platform business OmniAb continues to rack up the Big Pharma partnerships, with Eli Lilly signing off on up to $370 million biobucks tied to an ion channel program.

You might assume Chinese biotechs…

August 17th, 2026|FierceBiotech|

You might assume Chinese biotechs are enduring sleepless nights worrying about whether the ramping up of rhetoric in the U.S. is putting their new financial gains in peril. But the companies Fierce spoke to remained

AstraZeneca has stopped a phase 3…

August 17th, 2026|FierceBiotech|

AstraZeneca has stopped a phase 3 trial of volrustomig in lung cancer based on interim efficacy data, narrowing the opportunity for a bispecific designed to replace current immune checkpoint inhibitors.

Skye Bioscience has entered into…

August 14th, 2026|FierceBiotech|

Skye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new public company, called Fibrx Therapeutics.

Two recent patient deaths—both…

August 14th, 2026|FierceBiotech|

Two recent patient deaths—both involving severe immune reactions to high-dose, viral vector-delivered gene therapies and a lack of disclosures—have drawn international scrutiny to what appear to be systemic gaps in oversight and transparency within China’s

BioCryst CEO Charlie Gayer told…

August 14th, 2026|FierceBiotech|

BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.

Capricor Therapeutics has bounced…

August 14th, 2026|FierceBiotech|

Capricor Therapeutics has bounced back from a bruising FDA advisory committee meeting by securing a green light to file an amendment to its approval application, raising hopes that the biotech can rescue its Duchenne muscular

Despite mixed results for its…

August 14th, 2026|FierceBiotech|

Despite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs.

Just weeks after Legend Biotech…

August 13th, 2026|FierceBiotech|

Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed round

PDS Biotechnology has called a…

August 13th, 2026|FierceBiotech|

PDS Biotechnology has called a halt to its phase 3 head and neck cancer therapy to channel resources to a drug in phase 2 development for metastatic colorectal cancer.

PTC Therapeutics has struck a deal…

August 13th, 2026|FierceBiotech|

PTC Therapeutics has struck a deal to buy Sangamo Therapeutics’ Fabry disease program for $111 million upfront, outbidding Astellas and TerSera Therapeutics for the near-approval gene therapy. Sangamo, selling assets as part of its bankruptcy

Taiho Pharmaceutical and Cullinan…

August 13th, 2026|FierceBiotech|

Taiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing the partners up to challenge Johnson & Johnson for a lung cancer niche.

As the FDA mulls whether to…

August 13th, 2026|FierceBiotech|

As the FDA mulls whether to approve Takeda and Protagonist Therapeutics’ rusfertide, Zealand Pharma has sold its own rights to the blood cancer drug in return for $100 million.

Aardvark Therapeutics has…

August 12th, 2026|FierceBiotech|

Aardvark Therapeutics has confirmed it is walking away from recently terminated phase 3 trials, telling investors it has no plans to resume the studies “as previously designed” as it works to find a path forward

Definium Therapeutics’ LSD…

August 11th, 2026|FierceBiotech|

Definium Therapeutics’ LSD formula has gone two for two in its phase 3 program, notching a win in generalized anxiety disorder months after knocking a depression study out of the park.